Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
Read transcripts of webcasts and audiocasts
Read transcripts of webcasts and audiocasts
Disclaimer: This is a machine-generated transcript and may contain inaccuracies.
Thank you very much. And thank you very much out there for dialing in for CellaVision's quarterly report, Q4 2025, which obviously also includes the consolidated results for the entire 2025. A lot of good things have happened. And first of all, I want to formally welcome our newly appointed CFO, Monica Johnson, who is with me today, to participate. And of course, explain our business. Monica has been with us since autumn, and she was formally appointed CFO with CellaVision on December 12th. So that was the first good news. Hopping into the quarter. In brief, the Q4, we have entitled our quarterly report as a solid quarter driven by strong performance in Americas. So it's particularly in Americas. However, we also see a pretty strong performance in EMEA. While the quarter has been somewhat soft in APAC, and we will unfold that throughout today's call, we landed the quarter with net sales that increased by 5.6% to a revenue stream of 197 million SEK, which translates into an organic growth of 12.2%, given our headwind on the effects of -6.6%. So double-digit growth throughout this quarter. This translates into an EBITDA contribution of 65 million SEK, equivalent to 33 percentage points. In terms of the business, we will go into the business and explain both our P&L, our regional split, and give some highlights there. And of course, also cut it across the different product families. But I also want to give a little bit of insights as to our progress on our strategic direction. We accomplished a key milestone by getting CE mark for our new application for bone marrow aspirates. And so this is a class C product that is now registered according to the EU IVDR, which allows us to start launching the product this year or pretty much in the quarter we're in. We can talk more about this a little bit later. As noted in our latest report, we have also been working on a significant software upgrade for our hematology instruments. This has been successfully validated at a customer site. So, this really allows us to upgrade our fleet with a modern and user-friendly interface. Some new features, including higher speed on the new DI 90, DI 60 that comes out. First of all, I also want to emphasize that, since we are coming to the year-end, the Board of Directors proposes to increase our dividend from 2.5 last year to 2.75 Swedish krona per share. So this is what will be proposed at the annual general meeting taking place on the 28th of April. If we zoom in on the financial development for Q4, I've mentioned our revenue. And then if we hop in. So on the left hand side, we have the quarter we are reporting today, the comparable quarter. And then we've consolidated the entire full year report, with the comparative data from 2024, to the very right hand side for the full year. Our gross margin was 67%. It is a little bit lower than normal, a little bit hit by software. Especially from APAC, but also FX, takes us down a little bit here. Operating expenses landed at 39%. EBITDA is 33%, which is above our target of 30%. And then we on the R&D side, which is really very strategic for us. We've increased our R&D spend within this strategic period. So we're at 19% and up against the compare. It drops from 22. So it's actually 37 million in total R&D spend. But maybe I can ask you, Monica, to comment on our capitalization and maybe also our principles for capitalization. That might be appropriate. Sure.
So during the quarter, we incurred 15 million SEK in R&D costs. And as you can see, we capitalized more or less half of the R&D spend. And what is not capitalized is mainly related to projects that are in an early stage and also product care. And you will see during 2026 that we will start capitalizing some of the projects that are maturing and also start depreciating some projects that we are launching products such as bone marrow.
Excellent. So, on the cash flow side, operating cash flow of 51 million SEK slightly increased by 5 million versus our comparable quarter, and a total cash flow of 30 million SEK. So, going from the operating to the total, the majority of that is the cash that we invest and capitalize in R&D. That's what sits there. We have low, very low financing activities. So we have hardly any debt. And we end the year with a balance sheet that contains a cash position of 180.88 million SEK. Sorry. Our gross margin was 67%. Yeah. Here we are also showing the full year results. So we landed the year at 759 million SEK, which is an organic growth of 9% over the year, and a gross margin of 68%. And that provides a total cash flow of 40 million SEK. So obviously, we've paid out dividends. And we have also capitalized a considerable amount of R&D cost of 67 million throughout the year. So those are the main components that bring us to this total cash flow of 40 million. That is an organic growth of 15% throughout the quarter. Let's move on. Let's try and look at the regional performance across the three regions: Americas. So, North and South Americas, EMEA including the Middle East, and APAC. So our performance was very strong in Americas, in fact, an all-time high with 90 million SEK. That is an organic growth of 50% throughout the quarter. Also 50%. But then the headwind of currency effects. The organic growth was 58%. Very strong momentum in Americas, especially in the US, which you may also note in Sysmex's last couple of reports. Sysmex being our main strategic partner. So, that is the kind of business that is elevated. Our joint momentum. It is fair to say that it's extremely high. And that is also due to the presidential election in Q4. Yeah. So I think that's a fair comment to provide the full picture for EMEA. We had, there we also saw an increase both in small and large systems. And we obviously also had a contribution from reagents, but they actually impacted the quarter negatively. That is a Euro business. So we are primarily exposed to currency effects. And then there's a little bit of phasing on there. But I can talk more to reagent in a second. On APAC, we landed in a situation where we typically have high fluctuations depending on whether we ship to APAC, in particular China, or not. And here we landed in a pretty reasonable quarter, 28 million. However, it does represent an organic decline of 40%. And that is also due to a strong comparable quarter. You may recall that we had a one-off tender delivery for New South Wales in Q4 last year, which is why we organically declined so much, despite it being a reasonable quarter with deliverables somewhat spread across China and Southeast Asia. So, we continue to see growth of our expansion into APAC throughout this. A lot of countries, of course, have smaller volumes, but we are building our position with the installations across APAC. If I segment the same numbers per product family: instruments, reagents, software, and others. Here you do see that our total instrument revenue was 126 million. And we talked about the US and the other elements, but it gives us an idea of 8% growth for reagents. We actually were down 2% on the total business for the quarter, which translates into 6% growth on the year, so organically around 9%. EMEA decreased slightly. And as I said that is primarily currency. I would say, though, that our hematology, which is a growing portfolio, especially our hematology reagents, representing the bulk of the business—perhaps two-thirds—grew 10% for the majority of it across Europe and APAC, where our expansion with hematology reagents also delivered solid growth, albeit from smaller numbers. But we grew on the quarter from 1.4 million to 2 million compared to the comparable period, and that significantly increased our revenue in APAC. On the year for software and others. We had declining growth for software and others. It contains both spare parts as, of course, software and also consumables such as oil. But it also entails the currency effect, which impacts our numbers considerably from a comparable position. Specifically on the software. We were low in the comparable period, and there was a major contribution from APAC due to the large tender we provided last year, which also entailed a considerable amount of software. So this is also why we see the decline. Key takeaways. As we say, the fourth quarter is driven by strong performance in Americas. We said we landed our year with 9% organic growth. And in fact, if I really look at where we work and how we work with our strategic partner organizations. Our core strategy works. We are working. We are growing double digit. And with these partner organizations across the world, however, some product lines, such as non-hematology or other products, have slightly reduced our organic growth; yet, our direction is paying off. And that is also consistent with, or applies to, our Power of Focus strategy that we communicated in 2022. Here we invested a very ambitious investment programme in R&D and innovation. And one of the new levers was entering what we call the specialty analysis arena. So more applications to assist the hematology labs out there to diagnose blood-based disorders. The first product is out. That is the product for bone marrow, as I initially said. So we do believe that now we can start building the market for assisting in lymphoma diagnosis. Lymphomas and leukemias. And out there in the hematology lab and adjacent labs where they utilize this hematology solution or this bone marrow solution. So we are starting to launch first campaign wise, there will be training of our partner organizations. There will be building of a funnel. And then there will be evaluations for the healthcare professional to see how it assists their workflows. And then we do expect that in the second half of the year, we will start seeing revenues from this product from Europe. And then we're of course, also on that note, aiming for getting into the US. But more about that later. As mentioned also when we teed up the call, we have a major milestone in launching the software upgrade that delivers this faster and smarter workflow, cutting-edge user experience for the hematology labs and actually for the new DI-60 systems that is integrated with the hematology line of Sysmex. It offers an improved integration. But it also entails an improved throughput. So the number of blood samples that can be processed will increase on the new GI 60. So we believe we're well positioned to continue our journey in assisting the mid and high volume labs here. So, a very important key takeaway is repeating back to The Power of Focus strategy, specifically regarding our actions in early 2020 or spring 2022. We acquired the exclusive IP rights to a patent portfolio that was invented by Caltech. And we have deployed and further developed our technology in our hands. And as you can see in the way we communicate, we're extremely confident that this will really support our next generation hematology analyzers that are part of this major investment program that CellaVision has gone through and is going through. And furthermore, we are also very clear on our ambitions to expand and deploy our capabilities for adjacent areas. And here we are also confident to say that we truly believe that the way we pursue our vision of really pushing the evolution of microscopy. We have a disruptive microscopy solution in our hands, and we believe that is something we will continue to invest in. And we will also pursue future partnerships that can help us commercialize these technologies in the future. So with that, taken together, I believe we ended 2025 on a pretty strong note with 9% organic growth given everything that happened. And I'm actually very proud of the team, given the fact that we've done this with our existing portfolio, and we are seeing now that our innovation program pays off, and we are starting to launch all these new opportunities, which we're very confident will be a profound platform for future growth. With that, we will close this session and enter the Q&A.
If you wish to ask a question, please dial Pound Key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key on your telephone keypad. The next question comes from Ulrich Trattner from DNB Carnegie. Please go ahead.
Thank you very much. And a few questions on my end. And first of all, and I apologize, I struggled a little bit with the sound. Maybe it was just me. So, it might be things that you already addressed. But if I can start off with the DC one and the DC one momentum, particularly in the US, and your thoughts on current trading. And what you did see throughout Q4 was really improving. What do you derive that from? Are you seeing increased capacity from the labs to expand and invest versus last year, or the reasoning behind the current situation and demand flow?
Fair enough. And thanks for your question, Ulrich. I think we see a momentum also, given the softness we experienced a year ago. Then gradually over the last half of 2025, we've seen positive momentum communicated externally by Sysmex and how the market is operating in the clinical lab segment. And we've seen that translate into outcomes that also entail our solution, our integrated solution. And at the same time, we have seen the interest, let's say, come back on the DC one. And I think what is happening, and this is also something we are really starting to position, the targeted opportunities for the integrated health networks in the US. So they're having the labs that can digitalize the satellite labs. That is the value proposition. So there's one story around the workflow for the individual labs. But then what we're really seeing resonates in the US because they are digitalized to a relatively high degree, that is attaching these IHNs. And so all the integrated health networks, the distant satellite hospitals, this is where we believe there is a market that is, I shouldn't say untouched because we have certainly placed DC ones, but the opportunities are much larger than what we have placed so far.
And that's because hospitals place the order with Sysmex. That's great. And for the last few years, we have seen this prolonged order to installation trend. Has there been any shifts in that being shortened here, or is it still the same situation?
No, I think typically, from when orders are placed, let's say in the US, it is our belief and understanding that that is pretty much a phase of 2 to 6 months. Then we have been in a situation where it probably was longer, and now it seems like we're somewhat back to that kind of up to half a year. And that's because hospitals place the order with Sysmex. And then there's an installation project starting up. So that means that everyone involved coordinates the installation. has to come together. And then all the equipment, the cell counter, including CellaVision's cell morphology analyzer, needs to be in place. This is why, regarding Sysmex orders, the timeframe is approximately this. Up to half a year, and then it varies. We saw the tender we talked about in Australia that took five years. So it does vary. There are deviations to this rule of thumb.
And you touched upon this now with the software, denoted as 'Software and others' in your report, a little bit of weakness here in Q4 affecting the product mix. And as you alluded to the larger tendering in Australia, now you're rolling out an updated version. What to expect from that segment? I guess you would assume some big price increases for software heading into 26 versus 25.
Actually, that's not how we position this. We position this solution as part of the new DI-60s. So we want to be competitive and protect the installed base and also the replacement market. So this is not an upgrade where we charge. It's part of the D60 system. But what it does is it also allows the health network. So if you take a given hospital. With satellite hospitals, etc. If they upgrade to this software version 7.2. Then all their entire fleet, including the old instruments, will all of a sudden be utilizing a new user interface with the improvements that we are launching in the software. So this is a way to really provide additional customer experience prior to our next generation coming out. So we have considered that this is a better proposition as opposed to charging a price. We would rather increase prices when we come out with new hardware.
We believe we have a better way. We position ourselves best to capture the growth from the instrument placement instead. So that would entail that there's no price increase of the DI-60 either.
No, there will be price increases on the instruments. But we will not simply charge for software. We believe we have a better proposition. We position ourselves best, and we will capture the growth from the instrument placement instead.
And then just an accounting question here. And just to double-check if my maths aligned with yours. Because capitalized R&D historically has had an effect on the gross margin side. So, now when you're rolling out the bone marrow application, I'm approximately at a one percentage point headwind on the gross margin on the back of starting to depreciate that. Does that sound fair?
Yes, that sounds reasonable.
Great, a short answer, I like it. And then, last question on my end before going back into the Q&A: if you can provide some more granularity on the rollout of the CellaVision® Bone Marrow Aspirate (BMA) Application and the methanol-free reagents throughout 2026. Regarding the bone marrow, I know that you say that you will do a launch here in Q1, but are there any conferences in the near term where you're going to do more of a broad-based launch, as well as how is the training of Sysmex personnel progressing?
Great question. For the bone marrow, you're absolutely right. We'll start the BMA campaign in this quarter in March. We are in the process of training the Sysmex reps. And once that is done, then we will, of course, start to position our solutions in Europe across the different countries. There will be demos in the different individual labs. And then it's commercially available. Regarding conferences, we'll do the big launch at the EHA later in May. That's in May. So that's the big conference where we sort of make a splash, and then we will also be present at the ECP later in the year. But ISLH is the biggest launch event. Coming back to the quarter in Q4, I just want to express my appreciation for our partner organization, who has been with us on-site with Sysmex, where we presented the CellaVision Bone Marrow Aspirate Application. And then we actually obtained the CE marking for the bone marrow application just before Christmas, as opposed to Q1 as we had anticipated. But that is kudos to the team for actually driving this to be in our hands a little bit earlier, and also to Sysmex, who are really welcoming this significant product, including the methanol-free solutions. I can also, Ulrike, you asked about methanol free, right?
The story around the methanol-free stain. Is that, so our reagent revenue is primarily from the classic stains. And now we have this methanol-free stain. We've had it for years, in fact. But now there is an opportunity for methanol free to be running on the SP-50. So the smearing and staining device of Sysmex. And that has opened up for the opportunity to globalize methanol free. So this will be available. It's available in Europe. But this is also the opportunity to enter the US where we have hardly been selling any reagents. So this is obviously the plan we are currently executing in the US. We're currently tweaking the protocol. So the actual staining resembles what is preferred in the American market. Right? Right. It's still methanol free, but there's a little bit of tweak going on there. And then we plan to launch it this year. So this is the plan together with Sysmex. That is the game plan for them to get into the US.
So the smearing and staining device of Sysmex. Thank you for taking my questions on these topics, and I'll get back into the queue.
It's still methanol-free, but some tweaking is ongoing. The smearing and staining device of Sysmex.
The next question comes from Ludvig Lundgren from Nordea. So starting off on order intake, I believe you said you had a very strong order intake in Americas from the networks?
Yes. Hi, and thank you for taking my questions. So I have a few, and I'll take them one by one. So, starting off on order intake, I believe you said you had a very strong order intake in Americas from the networks? So I just wonder if it's possible to in some way quantify the book-to-bill here in the quarter, and whether it's fair to expect this strong order intake to translate to strong instrument placements also in H1 2026.
In general, there's some momentum in the Americas and especially in the US. So it's early days, and we don't typically disclose our order book for the current quarter. Having said that. I see no reason why the momentum for America should vanish. I think we're in a reasonable, solid situation there from what we hear from the market situation.
Okay, great. Thank you. And then I had a question on gross margins as well, a bit of a follow up. So softer here. in the quarter. And I just wonder, like, if it's possible to quantify how much of this relates to FX and how much of this relates to the softer software sales and the weaker product mix from that. Like in rough terms, it would be great.
Yeah. Comparing to last year, it's a lot of FX and somewhat product mix, exact relation here. I will not disclose, but a little more FX than product mix.
Okay. Great. Thank you. And then the final one from my side on the gross R&D. You talked a bit about it here, but I wonder, it was down to 37 million, down 9% year over year, I believe. Like, why was it down this quarter? And how should we think about the gross R&D level looking into 2026, and is 37 million a reasonable level to extrapolate?
Yeah. Actually, we see some decline in R&D spending in Q3 and Q4 versus last year's Q4, Q1, and Q2, and that is mainly due to the phase of one of our biggest projects where we had a lot of buying of consumables during Q4, Q1, and Q2. And then due to the phase of the project, we do not have that in Q3 and Q4. And then also, we have released some consultants that worked on the software upgrade project after Q2. But what we see going forward, we will see continued high R&D costs in 2026. We have many interesting projects that we are working on. So I would expect more in line with Q1, Q2, Q3 levels also during 2026. So Q4 is not significant. What will you expect for the next year, compared to this year? So more in line with the quarters?
Yes. And just to follow up on that, what is a fair capitalization rate to expect on these projects done in 2026?
Yeah, more or less at the same level.
Higher or lower. Yeah. But maybe just to clarify, did you say that we should expect, Simon, some contribution from the Bone Marrow Aspirate (BMA) Application in the EU here during the fiscal year in H2?
Probably the same level. The projects that Monica elaborates, some of them will be early stage, which means that we don't capitalize, and then some of them will actually make it throughout our development model. Then they will cross the line and start being capitalized. So there's a little bit of balance.
And then we have a few that were capitalized up until Q4 that are now depreciating. So that is then evening out.
Yeah.
But maybe just to clarify, did you say that we should expect some contribution from the bone marrow application in EU here during the fiscal year in H2? Most of the questions have been asked and answered already. Thank you very much. I'll jump back into the queue.
Thanks, Ludwig.
The next question comes from Simon Larson from Danske Bank. But maybe just to clarify, did you say that we should expect some contribution from the bone marrow application in EU here during the fiscal year in H2?
Yes. Hello, everyone. But maybe just to clarify, did you say that we should expect some contribution from the bone marrow application in EU here during the fiscal year in H2? Most of the questions have been asked and answered already. But maybe just to clarify, did you say that we should expect some contribution from the bone marrow application in EU here during the fiscal year in H2? Was that correct?
Yeah. It's so we're building up the funnel. But we do expect that. So the question is how long does it take for the labs to evaluate it before they place the order and ship to Sysmex? However, we are positive that we should start selling and see invoices, so to speak. In the second half and in particular in Q4, that's our ambition. Definitely.
I think also this was touched upon before, but the methanol-free reagents are now obviously available in the EU through Sysmex. Is this more also a second half thing, or could we see something here already in first half?
I'd say for EU, I think the methanol-free stain represents a growth opportunity in general because it's a better value proposition. However, given the market share we have in Europe, and there are markets where we have a very low market share, where there is plenty to do, and there are markets where we have very high market share. But we will cannibalize a little bit in Europe. So that's my point that we may try and transfer certain classic stain customers to methanol-free in Europe, in the US. We expect that we will gain share as we start pushing this, because there we have zero market share. We own the market together with Sysmex. But reagent-wise, this is when we start with methanol free. So there we will gradually gain customers as they convert their instruments and phase out their current reagents, then we expect to gradually place methanol-free stains. And that contribution for 2026 is probably somewhat limited because it's also dependent on the launch. And then there is a phase where the customer would like to try it out. So therefore, we would be a little bit conservative on estimates for contribution from methanol free in the US. I hope that that explains the situation. Simon.
No, definitely. Could you remind us roughly the difference in price between the methanol-free stain and the legacy stains, just in the case of cannibalization?
Yeah, no, I probably I'm not going to go to the pricing piece, also for competitive reasons, but there will be a little bit of a lift. But I would say, remember, this is, the hematology reagents are a little bit commoditized and it's high volume, but it's not sophisticated chemistry. So we will raise the price. But you cannot go for extraordinary margins. Sort of top margins in this market.
No, no. That's understood. And my final question relates to the FPM technology. You sound quite upbeat in the CEO letter, I think, regarding it and its prospects. So I was just curious to learn about what the potential partner could look like. Do you expect that to happen within the hematology market, where you are present already today with your current existing partners? Or could this also be a new partner in an adjacent area? Just high level, if you could say anything about that.
No, I think, yeah. High level. I'd say definitely the position we have where we lead the hematology space. We are very confident, and I'm glad to convey the positive and confident attitude because that's what we have. And so we are now at a stage where we are very confident to protect and grow our business in the hematology arena, and the adjacent areas. This is where we've also, throughout 2025 matured the technology to a level. So that we've talked about cytology, we've talked about pathology. We're confident that we can actually build instruments for those segments. But there are other adjacent areas in the clinical space and in the research space where we believe that the FPM technology, given its image quality, speed, depth of focus, and a number of other features, can disrupt those segments. Those will be players in the microbiology arena, in the pathology cytology arena, and in the life science space. Now we're in a situation where we can engage more fundamentally and more substantially with partners, because they can see what we can. And it's not just IP rights that we have acquired. So that's why we are pushing our communication a little bit further because we are confident that we sit on a disruptive microscopy solution here.
Just high level, if you could say anything about that. That makes sense. Thanks a lot. And that was all I had.
Of course, we are looking forward to disclosing partners or improvements as we go along. So. So yeah. So that's of course our goal.
The next question comes from Christian Li from Pareto Securities. Please go ahead.
Yes. Thank you. And thank you for taking my question. I have one follow up regarding the order intake, you mentioned that you reached record levels in the quarter from larger integrated networks in the US. Did you deliver most of it in Q4?
Yeah, that may be worthwhile. Communicating that the order intake is also shipped. And then we believe we still have momentum for Americas. So yes, what you see is what is shipped. That's what we book for Q4. So that is correct.
All right. But do you see any risk of inventory build up impact in Q1 in the US?
In the US? I say roughly speaking, maybe a little bit for smaller instruments. But not necessarily for the larger instruments.
All right. And could you please give us some comment on the outlook in the other regions regarding the instruments?
I think that's along the lines of what we've said with the momentum we've seen in the different regions. So we believe that translates into orders. Now the business is fluctuating a little bit. And for Americas, we have relatively good visibility. It's a little bit harder for us for Europe, because it's a consolidation of orders that comes from multiple countries operating via the supply chain of Sysmex. And then it comes to us. So there we actually have less visibility. What we hear is what we communicate. And we have seen it over the last couple of years that there's a fundamental interest in our solutions, and we see no reason why that shouldn't stop. And then, of course, we may have some fluctuations per quarter, but fundamentally, we believe we're in a pretty good situation, also now that we are launching new software. All right. That makes us believe in the future of APAC. We think we have good opportunities for incremental business in Australia and New Zealand. There could be some opportunities also in Japan. And then, as you know, we are now manufacturing our integrated system in China. So that allows us to participate in domestic tenders, where you have to be a domestic player and our products are registered in China as being from a Chinese legal entity. So, over time, we still believe in China. However, we also know that this is where our competitors are strong. So we're up against that in China. But it's a huge market. So we believe that there's certainly a position for Sysmex CellaVision out there.
That makes us believe in the future for APAC. However, we also know that this is where our competitors are strong.
Thanks, Christian.
The next question comes from Ludvig Lundgren from Nordea. The next question comes from Ludvig Lundgren from Nordea.
Yes. Hi. Just another follow up on the reagent side. So that was a bit weaker in Q4 when comparing to Q3. But Q3 was of course very strong. So I just wonder, is the average of these a fair assumption going ahead? Or, what would you say is the run rate of reagents currently?
No, I agree. I think Q4 was a little bit weak, both on the hematology side, even though it was 10% organically. But we were flat, if not negative, on the non-hematology proportion. So we had a big tender where we expected a shipment. We've been working on that throughout the year and where we didn't ship products. So we were a little bit negative on that. So Q4 stands out as somewhat of a soft quarter on the reagents, and we expect it to bounce back, and especially with the growth coming from the hematology, which represents approximately two thirds of our business.
Okay, great. And a follow-up to that, what is a fair growth rate that you would expect for the hematology business. Can this grow double digits?
Yeah, I'd say historically we've been landing it at probably lower double digit for the hematology. And I see no reason why we should not. It's a considerable business. So it takes more to change the growth, so to speak. However, with the gradual increase, we've seen the 80% growth we have on the hematology side in APAC, though it's a small contribution, obviously. Total revenue out there this year was 9 million. But still it's growing. And then, as we start over the next coming years to get into the US, I think that's where we can probably be even more ambitious of getting higher growth rates for the company in the revenue bucket. Because this is really incremental growth that comes in while we still believe that we have opportunities to grow double digit in Europe, where we have a profound footprint. So it's really a big thing for us that we can finally enter the US, given the fact that our Sysmex smearing device can now host the methanol-free stain. So it is exciting for the coming years to start and build that market.
And would you expect some incremental sales in the US already in 2026 from this?
Yes, I would expect it, but I don't want to overdo it. I'm much more, if I can see traction from those starting to use methanol-free, that would really be our goal. But it will translate into some revenue. But I would expect it at the end of the year. So that would put us in a situation where it's confirmed in the market and that gives us a good platform for growth contribution in 27. I think that's the way to look at it.
I want to finish up the call by saying that I think what we've demonstrated throughout the previous year, both in the commercial arena and through our investments, is the organization's ability to translate these investments into meeting very crucial strategic milestones. Very clear. I want to finish up the call by saying that what we've demonstrated throughout the previous year, both in the commercial arena and through our investments, highlights the organization's ability to translate those investments into meeting very crucial strategic milestones.
Pleasure.
There are no more questions at this time. So I hand the conference back to the speakers for any closing comments.
Thank you very much. And again, thank you everybody who called in and last but not least, to the good questions that gave us a meaningful report today for 2025. I want to finish up the call by saying that I think what we've demonstrated throughout the previous year, both in the commercial arena and in our investments, and the organization's ability to translate the investments into meeting very crucial strategic milestones. That means we are set up to continue our position of leading digital cell morphology into the future. So thanks to our teams for the relentless effort that you all do. But also thanks to our strategic partner organizations spanning from Japan and across all regions around the world. I think that is key. And then finally, I want to send my sincere thanks to our entire group of hematology professionals who are using our solutions on a daily basis. And amongst that segment, a special thanks to the ones who are providing us with feedback to our development programs, and or who have participated in our clinical validations, which has been a considerable part of the investments. Again, the good example is the CellaVision® Bone Marrow Aspirate CE mark that we, of course, want to leverage for a global product. So I really a big thanks to our employees, our partners, and our professionals that we work with as customers. So with that, thanks for dialing in. And we're looking forward to actually be back with the interim report on the 24th of April. And then we have our annual general meeting on April 28th. So thank you very much.



















